Literature DB >> 12878327

Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.

Mitchell Ho1, Mariangela Segre.   

Abstract

Conventional drug development for treatment of cocaine addiction is greatly hindered by the extreme difficulty in designing a selective cocaine antagonist. We employed anti-idiotypic (anti-Id) antibodies to generate cocaine antagonists. The purpose of this study was to investigate the feasibility of this alternative approach. Herein, we describe the molecular cloning, bacterial expression, and functional properties of an anti-Id monoclonal antibody (mAb), designated K2-3f, which possesses an internal image of cocaine within its variable regions. The heavy and light chain variable domains of K2-3f were cloned by reverse transcription-polymerase chain reaction (RT-PCR) and a single chain antibody variable fragment (scFv) was assembled for expression in Escherichia coli. The scFv bound to the human dopamine transporter (hDAT) with moderate affinity (K(a)=5.3 x 10(6) M(-1)) and excellent mimicry of the cocaine molecule completely inhibited cocaine binding at a molar concentration closely resembling in vivo conditions while allowing approximately 90% of equimolar dopamine uptake. Our data suggest that the use of anti-Id antibody as a template for generation of a cocaine antagonist is a promising approach well worth pursuing. If this strategy is successful, it could be applied to potential ligand-receptor interactions in the treatment of other diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878327      PMCID: PMC3295240          DOI: 10.1016/s0925-4439(03)00091-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  Molecular basis of antigen mimicry by an anti-idiotope.

Authors:  B A Fields; F A Goldbaum; X Ysern; R J Poljak; R A Mariuzza
Journal:  Nature       Date:  1995-04-20       Impact factor: 49.962

Review 2.  Internal image concept revisited.

Authors:  C A Bona
Journal:  Proc Soc Exp Biol Med       Date:  1996-10

3.  Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters.

Authors:  B Giros; Y M Wang; S Suter; S B McLeskey; C Pifl; M G Caron
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

4.  Characterization of a monoclonal anti-idiotypic antibody that mimics cyclosporine A in a single binding system.

Authors:  N A Cacalano; W L Cleveland; B F Erlanger
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

5.  The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain.

Authors:  F J Lee; Z B Pristupa; B J Ciliax; A I Levey; H B Niznik
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

6.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter.

Authors:  B Giros; S el Mestikawy; N Godinot; K Zheng; H Han; T Yang-Feng; M G Caron
Journal:  Mol Pharmacol       Date:  1992-09       Impact factor: 4.436

7.  Idiotypic mimicry and the assembly of a supramolecular structure: an anti-idiotypic antibody that mimics taxol in its tubulin-microtubule interactions.

Authors:  J G Leu; B X Chen; A W Diamanduros; B F Erlanger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

8.  Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.

Authors:  S Kitayama; S Shimada; H Xu; L Markham; D M Donovan; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

9.  [125I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain.

Authors:  K Y Little; J A Kirkman; F I Carroll; G R Breese; G E Duncan
Journal:  J Neurochem       Date:  1993-12       Impact factor: 5.372

10.  Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes.

Authors:  P C Wilson; O de Bouteiller; Y J Liu; K Potter; J Banchereau; J D Capra; V Pascual
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

View more
  3 in total

Review 1.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.

Authors:  Xinran Xiang; Mingqian Feng; Mildred Felder; Joseph P Connor; Yan-Gao Man; Manish S Patankar; Mitchell Ho
Journal:  J Cancer       Date:  2011-05-16       Impact factor: 4.207

3.  Beyond new chemical entities: advancing drug development based on functional versatility of antibodies.

Authors:  Salvador Eugenio C Caoili
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.